Spondyloarthritis & psoriatic arthritis
Use of Apremilast for the Treatment of Immune Checkpoint Inhibitor Psoriasis and Psoriatic Arthritis
Authors' conclusion
This study highlights the potential benefit of apremilast for the treatment of ICI-PsO, both de novo and PsO flare, with less of an apparent benefit for ICI-PsA.
Study context
- Population
- Patients treated with apremilast after immune checkpoint inhibitor psoriasis (ICI-PsO) and/or immune checkpoint inhibitor psoriatic arthritis (ICI-PsA), including those taking apremilast before ICI initiation and with preexisting autoimmune disease5 de novo ICI-PsO/PsA
- Participants
- 21 patients
- Exposure
- ICI-PsO vs ICI-PsA
- Outcome
- Response to apremilast (complete, partial or none) by improvement in Common Terminology Criteria for Adverse Events grading
Methodological detailsmulticentre
- Multicentre
Main finding
As reported in the abstract
De novo ICI-PsO and/or ICI-PsA: partial response or improvement in irAE
4 of 5
Preexisting disease, no apremilast before ICI (n=13), ICI-PsO only: complete or partial response
100%
Preexisting disease, no apremilast before ICI (n=13), ICI-PsA: complete or partial response
57%
Observational data: associations, not effects.
Further findings
Time to flare · majority of both groups had grade II severity
Relevant preexisting autoimmune disease (likely flare with ICI therapy)
- Patients with relevant preexisting autoimmune disease
- 16 of 21
Progression of cancer or death at last follow-up on apremilast (entire cohort)
- Progression of cancer or death
- 38%
Safety
Intolerances in de novo patients with response
- Intolerances among the 4 de novo responders
- 3
Discontinuation of apremilast due to intolerability (entire cohort)
- Discontinued due to intolerability
- 29%
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →